Bristol Myers Squibb Launches “Change the Target. Change What’s Possible.” Campaign to Address Unmet Needs in Cardiovascular and Thromboembolic Care Bristol Myers Squibb announced today the launch of “Change the Target. Change What’s Possible.” an educational campaign developed in partnership with Johnson…
Real-World Head-to-Head Analysis Reveals 51% Lower Risk of Death in Metastatic Castration-Sensitive Prostate Cancer Patients Treated with ERLEADA® (Apalutamide) Compared to Darolutamide—Without Docetaxel—Over 24 Months Johnson & Johnson today announced new real world head-to-head evidence demonstrating that patients with metastatic castration-sensitive…
Finerenone Recommended in the EU for Heart Failure Patients with LVEF ≥40% Bayer today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending finerenone (Kerendia™), a…
DARZALEX FASPRO® quadruplet approved in U.S. for transplant-ineligible newly diagnosed multiple myeloma Johnson & Johnson announced today the U.S. Food and Drug Administration (FDA) approved DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) in combination with bortezomib, lenalidomide and dexamethasone (D-VRd) for the treatment of…
Bayer and Vanderbilt University Medical Center Collaborate to Advance Therapies for Cardiovascular and Kidney Diseases Bayer and Vanderbilt University Medical Center (VUMC) today announced that they have entered a strategic five-year collaboration agreement to advance innovative therapies from target identification…
ENHERTU® Plus Pertuzumab Moves Closer to EU Approval as First-Line Therapy for HER2-Positive Metastatic Breast Cancer In a significant milestone for oncology innovation, the European Medicines Agency (EMA) has officially validated the Type II Variation marketing authorization application for ENHERTU®…
Celltrion Unveils Innovative Drug Pipeline and Expands U.S. Manufacturing and R&D Strategy at 44th Annual J.P. Morgan Healthcare Conference Celltrion, a leading global biopharmaceutical company, today presented key strategic priorities and clinical development updates for its innovative drug pipelines including…
TECVAYLI® Monotherapy Shows Superior Survival vs. Standard Care in Early Relapsed, Heavily Pretreated Multiple Myeloma Johnson & Johnson, a worldwide leader in multiple myeloma therapies, today announced positive topline results from the investigational Phase 3 MajesTEC-9 study of TECVAYLI® (teclistamab-cqyv) monotherapy,…
Biogen Secures European Commission Approval for High-Dose SPINRAZA® (nusinersen) Regimen in Spinal Muscular Atrophy Biogen Inc. today announced the European Commission (EC) has granted marketing authorization for a high dose regimen of SPINRAZA® (nusinersen) which is comprised of 50 mg/5 mL…
NVIDIA and Lilly Launch Joint AI Lab to Transform Drug Discovery in the AI Era NVIDIA and Eli Lilly and Company today announced a first-of-its-kind AI co-innovation lab focused on applying AI to tackle some of the most enduring challenges…
Japan Approves Exdensur (depemokimab) for Severe Asthma and Nasal Polyps GSK plc has announced that Japan’s Ministry of Health, Labour and Welfare has approved Exdensur (depemokimab) for the treatment of bronchial asthma and chronic rhinosinusitis with nasal polyps (CRSwNP). The…
Johnson & Johnson Acquires Halda Therapeutics, Gaining Innovative Platform to Transform Cancer Treatment and Advance Next-Generation Oral Therapies Johnson & Johnson today announced the successful completion of its acquisition of Halda Therapeutics OpCo, Inc. (“Halda”), a clinical-stage biotechnology company with a…